{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:06:16Z","timestamp":1763003176876,"version":"3.45.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":476,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jtct.2022.01.005","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T03:00:59Z","timestamp":1643684459000},"page":"57-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Autologous Stem Cell Transplantation in Light Chain Amyloidosis: The Ultimate Treatment?"],"prefix":"10.1016","volume":"28","author":[{"given":"Cindy","family":"Varga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8354","key":"10.1016\/j.jtct.2022.01.005_bib0001","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jtct.2022.01.005_bib0002","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V70.3.869.869","article-title":"High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma","volume":"70","author":"Barlogie","year":"1987","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2022.01.005_bib0003","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2022.01.005_bib0033","first-page":"76","article-title":"Retrospective analysis of autologous stem cell transplantation for al amyloidosis: a study from the multiple myeloma working group of the japan society for hematopoietic cell transplantation","volume":"28","author":"Fuchida","year":"2022","journal-title":"Trans Cell Ther"},{"issue":"20","key":"10.1016\/j.jtct.2022.01.005_bib0004","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jtct.2022.01.005_bib0005","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time","volume":"36","author":"Sidiqi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.jtct.2022.01.005_bib0006","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study","volume":"33","author":"D'Souza","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2022.01.005_bib0007","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.bbmt.2017.11.040","article-title":"Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis","volume":"24","author":"Yeh","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2022.01.005_bib0008","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1200\/JCO.2010.31.4161","article-title":"Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection","volume":"29","author":"Bashir","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.01.005_bib0009","first-page":"1","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","author":"Sanchorawala","year":"2021","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.jtct.2022.01.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25404","article-title":"Combination of bortezomib in the induction, conditioning and consolidation with autologous hematopoietic stem cell transplantation in patients with immunoglobulin light chain amyloidosis","volume":"94","author":"Huang","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2022.01.005_bib0011","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1704346","article-title":"High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial","volume":"33","author":"Sanchorawala","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2022.01.005_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2019.01.007","article-title":"Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis","volume":"25","author":"Gupta","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.005_bib0013","article-title":"Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Pahse 3 ANDROMEDA Study","author":"Comenzo","year":"2021","journal-title":"ASH Annual Astract"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722000057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722000057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:01:41Z","timestamp":1763002901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722000057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2666636722000057"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.01.005","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous Stem Cell Transplantation in Light Chain Amyloidosis: The Ultimate Treatment?","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}